Pro Dex Net Income From Continuing Ops Over Time
| PDEX Stock | USD 39.48 1.39 3.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pro Dex Performance and Pro Dex Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pro Dex. Anticipated expansion of Pro directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pro Dex assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.082 | Earnings Share 3.41 | Revenue Per Share | Quarterly Revenue Growth 0.111 | Return On Assets |
Investors evaluate Pro Dex using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pro Dex's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Pro Dex's market price to deviate significantly from intrinsic value.
It's important to distinguish between Pro Dex's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pro Dex should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pro Dex's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Pro Dex and related stocks such as Sharps Technology, Sera Prognostics, and Microbot Medical Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STSS | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (4.7 M) | (4.6 M) | (7.6 M) | (9.3 M) | (8.4 M) | (8.8 M) |
| SERA | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (19.8 M) | (34.3 M) | (44.1 M) | (36.2 M) | (32.9 M) | (29.6 M) | (31.1 M) |
| MBOT | (21.3 M) | (21.3 M) | (28.5 M) | (26.4 M) | (32.3 M) | (36.4 M) | 9.6 M | (2.9 M) | 7.2 M | (7.3 M) | (9.2 M) | (11.3 M) | (13.2 M) | (10.6 M) | (11.4 M) | (13.2 M) | (13.8 M) |
| LUCD | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (8.3 M) | (28.1 M) | (56.2 M) | (56.8 M) | (45.5 M) | (41 M) | (43 M) |
| CGTX | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (7.8 M) | (11.7 M) | (43.6 M) | (22.8 M) | (34 M) | (30.6 M) | (32.1 M) |
| APYX | 109 K | 109 K | 617 K | (7.6 M) | (17.3 M) | (5.4 M) | (4 M) | (5.1 M) | (9.5 M) | (19.7 M) | (11.9 M) | (15.2 M) | (23.3 M) | (15.3 M) | (23.6 M) | (21.2 M) | (20.1 M) |
| GLSI | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (3.4 M) | (1.9 M) | (4.6 M) | (7.8 M) | (8.9 M) | (15.8 M) | (14.2 M) | (13.5 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (67.3 K) | (13.7 M) | (15.8 M) | (15 M) |
| IXHL | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.7 M) | (3.9 M) | (8.2 M) | (21.7 M) | (20 M) | (18.5 M) | (18.5 M) | (16.6 M) | (17.4 M) |
| RPID | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (37.1 M) | (73.5 M) | (60.8 M) | (60.7 M) | (46.9 M) | (42.2 M) | (44.3 M) |
Pro Dex and related stocks such as Sharps Technology, Sera Prognostics, and Microbot Medical Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Pro Dex | PDEX |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 2361 McGaw Avenue, |
| Exchange | NASDAQ Exchange |
USD 39.48
Additional Tools for Pro Stock Analysis
When running Pro Dex's price analysis, check to measure Pro Dex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pro Dex is operating at the current time. Most of Pro Dex's value examination focuses on studying past and present price action to predict the probability of Pro Dex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pro Dex's price. Additionally, you may evaluate how the addition of Pro Dex to your portfolios can decrease your overall portfolio volatility.